Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure Insights From the EMPA-REG OUTCOME Trial

被引：42

作者：

Butler, Javed ^{[1
]}

Zannad, Faiez ^{[2
]}

Fitchett, David ^{[3
]}

Zinman, Bernard ^{[4
]}

Koitka-Weber, Audrey ^{[5
,6
,7
]}

von Eynatten, Maximilian ^{[5
]}

Zwiener, Isabella ^{[8
]}

George, Jyothis ^{[5
]}

Brueckmann, Martina ^{[5
,9
]}

Cheung, Alfred K. ^{[10
]}

Wanner, Christoph ^{[7
]}

机构：

[1] Univ Mississippi, Med Ctr, Dept Med, 2500 N State St, Jackson, MS 39216 USA

[2] Inst Lorrain Coeur & Vaisseaux, Nancy, France

[3] Univ Toronto, Div Cardiol, St Michaels Hosp, Toronto, ON, Canada

[4] Univ Toronto, Lunenfeld Tanenbaum Res Inst, Mt Sinai Hosp, Toronto, ON, Canada

[5] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[6] Monash Univ, Dept Diabet, Cent Clin Sch, Melbourne, Vic, Australia

[7] Wurzburg Univ Clin, Dept Med, Wurzburg, Germany

[8] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[9] Heidelberg Univ, Fac Med, Mannheim, Germany

[10] Univ Utah, Div Nephrol & Hypertens, Salt Lake City, UT USA

来源：

CIRCULATION-HEART FAILURE | 2019年 / 12卷 / 06期

关键词：

cardiovascular diseases; chronic kidney disease; diabetes mellitus; type; 2; heart failure; sodium-glucose transporter 2; ESTABLISHED CARDIOVASCULAR-DISEASE; COTRANSPORTER; 2; INHIBITION; DIABETES-MELLITUS; HOSPITALIZATION; RISK;

D O I：

10.1161/CIRCHEARTFAILURE.118.005875

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: In EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) empagliflozin significantly reduced the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes mellitus and established cardiovascular disease. Post hoc, we evaluated empagliflozin on kidney outcomes in patients with or without heart failure (HF). Methods and Results: Individuals were randomized to empagliflozin 10 mg, 25 mg, or placebo. Prespecified analyses by baseline HF status included risk of incident or worsening nephropathy and estimated glomerular filtration rate slope analyses. Cox proportional hazards models assessed consistency of treatment effect across subgroups. Safety evaluations included kidney-related adverse events. At baseline, 244 (10.5%) and 462 (9.9%) patients had HF in the placebo and empagliflozin groups, respectively. Overall, the incidence of kidney outcome events was numerically higher in patients with than without HF. In the HF group, empagliflozin reduced risk of incident or worsening nephropathy or cardiovascular death by 43% (hazard ratio, 0.57 [95% CI, 0.42-0.77]) and progression to macroalbuminuria by 50% (hazard ratio, 0.50 [0.33-0.75]). After an initial transient decrease, estimated glomerular filtration rate stabilized over time with empagliflozin but gradually declined with placebo. Kidney effects in patients with HF were consistent with those in the overall study population (all P values for interaction >0.05). Across groups, the incidence rate of kidney-related adverse events/100 patient-years was higher in patients with than without HF; however, overall rates were comparable between groups. Conclusions: These findings from EMPA-REG OUTCOME support the hypothesis that empagliflozin could reduce the risk of clinically relevant kidney events and may slow progression of chronic kidney disease in individuals with type 2 diabetes mellitus regardless of HF status.

引用

页数：11

共 23 条

[1] The Global Health and Economic Burden of Hospitalizations for Heart Failure Lessons Learned From Hospitalized Heart Failure Registries [J].

Ambrosy, Andrew P. ;

Fonarow, Gregg C. ;

Butler, Javed ;

Chioncel, Ovidiu ;

Greene, Stephen J. ;

Vaduganathan, Muthiah ;

Nodari, Savina ;

Lam, Carolyn S. P. ;

Sato, Naoki ;

Shah, Ami N. ;

Gheorghiade, Mihai .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) :1123-1133

[2] The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors [J].

Butler, Javed ;

Hamo, Carine E. ;

Filippatos, Gerasimos ;

Pocock, Stuart J. ;

Bernstein, Richard A. ;

Brueckmann, Martina ;

Cheung, Alfred K. ;

George, Jyothis T. ;

Green, Jennifer B. ;

Januzzi, James L. ;

Kaul, Sanjay ;

Lam, Carolyn S. P. ;

Lip, Gregory Y. H. ;

Marx, Nikolaus ;

McCullough, Peter A. ;

Mehta, Cyrus R. ;

Ponikowski, Piotr ;

Rosenstock, Julio ;

Sattar, Naveed ;

Salsali, Afshin ;

Scirica, Benjamin M. ;

Shah, Sanjiv J. ;

Tsutsui, Hiroyuki ;

Verma, Subodh ;

Wanner, Christoph ;

Woerle, Hans-Juergan ;

Zannad, Faiez ;

Anker, Stefan D. .

EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (11) :1390-1400

[3] Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial [J].

Cherney, David Z. I. ;

Zinman, Bernard ;

Inzucchi, Silvio E. ;

Koitka-Weber, Audrey ;

Mattheus, Michaela ;

von Eynatten, Maximilian ;

Wanner, Christoph .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (08) :610-621

[4] Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus [J].

Cherney, David Z. I. ;

Perkins, Bruce A. ;

Soleymanlou, Nima ;

Maione, Maria ;

Lai, Vesta ;

Lee, Alana ;

Fagan, Nora M. ;

Woerle, Hans J. ;

Johansen, Odd Erik ;

Broedl, Uli C. ;

von Eynatten, Maximilian .

CIRCULATION, 2014, 129 (05) :587-597

[5] Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure [J].

Damman, Kevin ;

Gori, Mauro ;

Claggett, Brian ;

Jhund, Pardeep S. ;

Senni, Michele ;

Lefkowitz, Martin P. ;

Prescott, Margaret F. ;

Shi, Victor C. ;

Rouleau, Jean L. ;

Swedberg, Karl ;

Zile, Michael R. ;

Packer, Milton ;

Desai, Akshay S. ;

Solomon, Scott D. ;

McMurray, John J., V .

JACC-HEART FAILURE, 2018, 6 (06) :489-498

[6] Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME® trial [J].

Fitchett, David ;

Butler, Javed ;

van de Borne, Philippe ;

Zinman, Bernard ;

Lachin, John M. ;

Wanner, Christoph ;

Woerle, Hans J. ;

Hantel, Stefan ;

George, Jyothis T. ;

Johansen, Odd Erik ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. ;

Lienart, F. .

EUROPEAN HEART JOURNAL, 2018, 39 (05) :363-370

[7] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial [J].

Fitchett, David ;

Zinman, Bernard ;

Wanner, Christoph ;

Lachin, John M. ;

Hantel, Stefan ;

Salsali, Afshin ;

Johansen, Odd Erik ;

Woerle, Hans J. ;

Broedl, Uli C. ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. ;

Lienart, F. ;

Mortelmans, J. .

EUROPEAN HEART JOURNAL, 2016, 37 (19) :1526-1534

[8] Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis [J].

Hallow, Karen M. ;

Helmlinger, Gabriel ;

Greasley, Peter J. ;

McMurray, John J. V. ;

Boulton, David W. .

DIABETES OBESITY & METABOLISM, 2018, 20 (03) :479-487

[9] Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications [J].

Heerspink, Hiddo J. L. ;

Perkins, Bruce A. ;

Fitchett, David H. ;

Husain, Mansoor ;

Cherney, David Z. I. .

CIRCULATION, 2016, 134 (10) :752-772

[10] Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes [J].

Heise, T. ;

Seewaldt-Becker, E. ;

Macha, S. ;

Hantel, S. ;

Pinnetti, S. ;

Seman, L. ;

Woerle, H. J. .

DIABETES OBESITY & METABOLISM, 2013, 15 (07) :613-621

← 1 2 3 →